Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans
文献类型:期刊论文
作者 | Zhang, Yingying4,5; Yun, Xi5; Ouyang, Lu5; Zhang, Xianjing5; Gong, Likum1,2,3,4,5; Qin, Qiuping5![]() |
刊名 | ANALYTICAL BIOCHEMISTRY
![]() |
出版日期 | 2024-07-01 |
卷号 | 690页码:8 |
关键词 | Antibody-drug conjugate Camptothecin Exatecan Bioanalysis Pharmacokinetics |
ISSN号 | 0003-2697 |
DOI | 10.1016/j.ab.2024.115530 |
通讯作者 | Gong, Likum(lkgong@cdser.simm.ac.cn) ; Qin, Qiuping(qpqin@cdser.simm.ac.cn) |
英文摘要 | The successful development of Sacituzumab Govitecan and Trastuzumab Deruxtecan has made camptothecin derivatives one of the most popular payloads for antibody-drug conjugates (ADCs). Camptothecin and its derivatives all exist in a pH-dependent equilibrium between the carboxylate and lactone forms. Such transformation may lead to differences in the ratio of the two molecular forms in calibration standards and biological matrix (bio-matrix) samples, thereby leading to inaccurate conjugated antibody results. In this study, we reported an enzyme-linked immunosorbent assay (ELISA) free of the aforementioned influence for the detection of the Exatecans-conjugated antibody (conjugated SM001) in cynomolgus monkey serum. The assay was developed by first acidifying all samples with glacial acetic acid (HAc), then performing neutralization and thereafter capturing conjugated SM001 with anti-Exatecan monoclonal antibody (mAb) and detecting it with biotinylated Nectin4 (hNectin4-Bio) and horseradish peroxidase-labeled streptavidin (SA-HRP). Results showed that all tested performance parameters met the acceptance criteria. The conjugated SM001 concentrations obtained were in parallel to but slightly lower than total antibody (TAb) throughout the pharmacokinetic (PK) study, revealing that the assay strategy implemented for conjugated SM001 measurement worked well for the elimination of interference triggered by the heterogeneous existence of the lactone and carboxylate forms of Exatecan (lactoneExatecan and carboxylate-Exatecan). |
WOS关键词 | SACITUZUMAB GOVITECAN ; TOPOISOMERASE-I ; CAMPTOTHECIN |
WOS研究方向 | Biochemistry & Molecular Biology ; Chemistry |
语种 | 英语 |
WOS记录号 | WOS:001227551600001 |
出版者 | ACADEMIC PRESS INC ELSEVIER SCIENCE |
源URL | [http://119.78.100.183/handle/2S10ELR8/311063] ![]() |
专题 | 新药研究国家重点实验室 |
通讯作者 | Gong, Likum; Qin, Qiuping |
作者单位 | 1.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China 2.Univ Chinese Acad Sci, Beijing 101408, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 4.Nanjing Univ Chinese Med, Nanjing 210023, Jiangsu Provinc, Peoples R China 5.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Safety Evaluat & Res, Dept Immunoassay & Immunochem, Shanghai 201203, Peoples R China |
推荐引用方式 GB/T 7714 | Zhang, Yingying,Yun, Xi,Ouyang, Lu,et al. Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans[J]. ANALYTICAL BIOCHEMISTRY,2024,690:8. |
APA | Zhang, Yingying,Yun, Xi,Ouyang, Lu,Zhang, Xianjing,Gong, Likum,&Qin, Qiuping.(2024).Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans.ANALYTICAL BIOCHEMISTRY,690,8. |
MLA | Zhang, Yingying,et al."Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans".ANALYTICAL BIOCHEMISTRY 690(2024):8. |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。